Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9737562 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9737048 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL2166333 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9736549 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9737427 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9736910 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL536483 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9738506 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9739554 | 1.00 | MPI (0.37) | MPILMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL9737848 | 0.95 | LMNA (0.37) | MPILMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465616-B1 | TREATMENT OF STATIN SIDE EFFECTS USING URIDINE DERIVATIVES | MAGRAL LTD (AU) | 2010-06-30 | — | — | EP | claimed |
| EP-1054062-B1 | GLYCOSYLTRANSFERASE AND DNA ENCODING THE SAME | KYOWA HAKKO BIO CO LTD (JP) | 2009-06-03 | — | — | EP | claimed |
| US-7238100-B2 | β1,3-galactosyltransferase and DNA encoding the same | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-03 | — | — | US | claimed |
| US-20240336946-A1 | SOLID-PHASE GLYCAN REMODELING OF GLYCOPROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-10-10 | — | — | US | disclosed |
| EP-4110391-A1 | ENZYMES FOR SIALYLATION OF GLYCANS | Momenta Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2009025646-A1 | ALPHA 1-3 N-GALACTOSYLTRANSFERASE WITH ALTERED DONOR SPECIFICITIES | GOVERNMENT OF THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-1801118-A1 | PROCESS FOR SYNTHESIS OF MUCIN-TYPE PEPTIDES AND MUC1-RELATED GLYCOPEPTIDES | SHIONOGI & CO., LTD. (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-0506772-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A PHOSPHOSUGAR | PERSTORP AB (SE) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991009604-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A PHOSPHOSUGAR | PERSTORP AB (SE) | 1991-07-11 | — | — | WO | disclosed |